Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MAGEF1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA561368
Description
Immunogen sequence: MLQTPESRGL PVPQAEGEKD GGHDGETRAP TASQERPKEE LGAGREEGAA EPALTRKGA Highest antigen sequence identity to the following orthologs: Mouse - 34%, Rat - 32%.
Melanoma-associated antigen (MAGE) are completely silent in normal tissues, with the exception of male germ cells, and, for some of them, placenta. These antigens ought to be strictly tumor specific, expressed in tumor cells of various histological types. Because of their specific expression on tumor cells, these antigens are of particular interest for antitumor immunotherapy. Genes of the MAGE family direct the expression of tumor antigens that are recognized on a human melanoma by autologous cytolytic T lymphocytes. Though the function of MAGE is unknown, may play a role in embryonal development and tumor transformation or aspects of tumor progression.
Specifications
MAGEF1 | |
Polyclonal | |
Unconjugated | |
MAGEF1 | |
6430590I03Rik; MAGE family member F1; MAGEF1; MAGE-F1; MAGE-F1 antigen; MAGF1; melanoma antigen family F, 1; melanoma antigen family F1; melanoma-associated antigen F1; MGC19617 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
64110 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
0.1 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q9HAY2 | |
MAGEF1 | |
Recombinant protein corresponding to Human MAGEF1. Recombinant protein control fragment (Product #RP-100247). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction